Caprock Group LLC Trims Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Caprock Group LLC lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 59.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,503 shares of the medical device company’s stock after selling 5,092 shares during the period. Caprock Group LLC’s holdings in DexCom were worth $235,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in DXCM. Legal & General Group Plc lifted its holdings in DexCom by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after purchasing an additional 49,076 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of DexCom by 16.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after buying an additional 353,019 shares in the last quarter. Vaughan Nelson Investment Management L.P. boosted its position in shares of DexCom by 14.4% in the second quarter. Vaughan Nelson Investment Management L.P. now owns 1,617,001 shares of the medical device company’s stock valued at $183,336,000 after acquiring an additional 203,043 shares during the period. Rathbones Group PLC grew its stake in DexCom by 5.8% during the second quarter. Rathbones Group PLC now owns 1,401,802 shares of the medical device company’s stock valued at $158,936,000 after acquiring an additional 76,727 shares in the last quarter. Finally, Swiss National Bank increased its holdings in DexCom by 3.4% during the 3rd quarter. Swiss National Bank now owns 1,180,400 shares of the medical device company’s stock worth $79,134,000 after acquiring an additional 39,000 shares during the period. 97.75% of the stock is owned by institutional investors.

DexCom Price Performance

DXCM opened at $72.83 on Monday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The stock’s 50 day simple moving average is $70.61 and its 200 day simple moving average is $89.55. The firm has a market cap of $28.45 billion, a price-to-earnings ratio of 43.61, a PEG ratio of 2.28 and a beta of 1.17.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sadie Stern sold 4,259 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,431 shares of company stock worth $399,319. Insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on DXCM shares. Raymond James reduced their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. JPMorgan Chase & Co. boosted their price objective on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Leerink Partners lowered their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Stifel Nicolaus boosted their price target on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. Finally, Robert W. Baird raised their price objective on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, August 5th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.